Yang Honglin, Song Erlin, Shen Guorong, Zhu Tonghua, Jiang Tingwang, Shen Hao, Niu Liping, Wang Biao, Lu Zhaoyang, Qian Jianping
Department of Laboratory Medicine, The first people's Hospital of Wujiang District, Suzhou.
Department of Urinary Surgery, The First Affiliated Hospital of Harbin Medical University; Key Laboratory of Cardiovascular Medicine Research, Harbin Medical University, Ministry of Education, Harbin.
Onco Targets Ther. 2017 Feb 2;10:579-590. doi: 10.2147/OTT.S115791. eCollection 2017.
The clear cell renal cell carcinoma (ccRCC) is one of the most fatal urologic tumors, and the prognosis remains very poor for advanced or metastatic ccRCC. This study reveals the roles of microRNA (miR)-30c in regulating a highly aggressive ccRCC cell line proliferation by targeting MTA-1, which is a key mediator for human cancer metastasis. Results from quantitative real-time polymerase chain reaction showed that the expression of MTA-1, the target of miR-30c, was significantly higher in metastatic ccRCC specimens than in nonmetastatic ccRCC or nontumor specimens. Accordingly, endogenous miR-30c is at a much lower level in highly aggressive ccRCC Caki-1 cells than nontumor or ccRCC cell lines. Expression of miR-30c via lentivirus vector inhibits the proliferation, anchorage-independent growth, in vitro invasion or migration, or in vivo growth of Caki-1 cells by repressing MTA-1 protein expression. miR-30c also enhances the sensitivity of Caki-1 cells to anticancer agents, including sorafenib and paclitaxel. These data reveal the potential application of miR-30c and that its targeting gene, MTA-1, would be a potential target in metastatic ccRCC treatment.
透明细胞肾细胞癌(ccRCC)是最致命的泌尿系统肿瘤之一,对于晚期或转移性ccRCC,其预后仍然很差。本研究揭示了微小RNA(miR)-30c通过靶向MTA-1来调节高度侵袭性ccRCC细胞系增殖的作用,MTA-1是人类癌症转移的关键介质。定量实时聚合酶链反应结果显示,miR-30c的靶标MTA-1在转移性ccRCC标本中的表达明显高于非转移性ccRCC或非肿瘤标本。因此,内源性miR-30c在高度侵袭性ccRCC Caki-1细胞中的水平远低于非肿瘤或ccRCC细胞系。通过慢病毒载体表达miR-30c可通过抑制MTA-1蛋白表达来抑制Caki-1细胞的增殖、非锚定依赖性生长、体外侵袭或迁移以及体内生长。miR-30c还可增强Caki-1细胞对包括索拉非尼和紫杉醇在内的抗癌药物的敏感性。这些数据揭示了miR-30c的潜在应用,并且其靶向基因MTA-1将成为转移性ccRCC治疗的潜在靶点。